Cambridge biotech Nuclera and Swiss company leadXpro have joined forces in a bid to fast-track membrane protein programmes.
News Medical on MSN
Nuclera and leadXpro partner to accelerate structure-based drug design for complex membrane proteins
Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific ...
Industrial yeasts are a powerhouse of protein production, used to manufacture vaccines, biopharmaceuticals, and other useful compounds. In a new study, MIT chemical engineers have harnessed artificial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results